galcanezumab


( Last Updated : November 18, 2021)
Generic Name:
galcanezumab
Project Status:
Active
Therapeutic Area:
Prevention of migraine
Manufacturer:
Eli Lilly Canada Inc. (Lilly)
Brand Name:
Emgality
Project Line:
Reimbursement Review
Project Number:
SR0693-000
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Eli Lilly Canada Inc. (Lilly) is requesting reimbursement for EMGALITY® (galcanezumab) for the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Emgality is indicated for the prevention of migraine in adults who have at least four migraine days per month.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Key Milestone

Call for patient/clinician input open 05-May-21
Call for patient/clinician input closed 28-Jun-21
Clarification:

- Patient input submission received from Migraine Canada Migraine Quebec

Submission received 03-Jun-21
Submission accepted  
Review initiated 18-Jun-21
Draft CADTH review report(s) provided to sponsor for comment 02-Sep-21
Deadline for sponsors comments 14-Sep-21
CADTH responses on draft review report(s) provided to sponsor 15-Oct-21
Expert committee meeting (initial) 27-Oct-21
Draft recommendation issued to sponsor 09-Nov-21
Draft recommendation posted for stakeholder feedback 18-Nov-21
End of feedback period 02-Dec-21